Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sabine Haggenburg, Hannah M. Garcia Garrido, Iris M. J. Kant, Hanneke M. Van der Straaten, Fransien De Boer, Sabina Kersting, Djamila Issa, Doreen Te Raa, Hein P. J. Visser, Arnon P. Kater, Abraham Goorhuis, Koen De Heer
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-07-01
Saila:	Vaccines
Gaiak:	chronic lymphocytic leukemia pneumococcal vaccination immunogenicity antibody response
Sarrera elektronikoa:	https://www.mdpi.com/2076-393X/11/7/1201
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!